Search results
WIXELA INHUB 250/50 is a twice-daily prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.
This review discusses Wixela™ Inhub™, a generic equivalent of Advair Diskus ®, a fixed-dose combination of fluticasone propionate/salmeterol powder for oral inhalation for patients with asthma and chronic obstructive pulmonary disease (COPD).
7 gru 2020 · Background: Wixela™ Inhub™ is a fluticasone propionate/salmeterol dry powder inhaler developed as a generic equivalent of Advair Diskus® for the treatment of asthma and chronic obstructive ...
4 gru 2023 · Chronic Obstructive Pulmonary Disease (COPD) ADVAIR DISKUS 250 and ADVAIR DISKUS 500 are indicated for: the maintenance treatment of COPD, including emphysema and chronic bronchitis, in patients where the use of a combination product is considered appropriate. ADVAIR DISKUS should not be used as a rescue medication.
ADVAIR DISKUS is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in adults and children aged 4 years and older. ADVAIR DISKUS contains salmeterol, the same medicine found in SEREVENT DISKUS (salmeterol xinafoate inhalation powder).
Maintenance Treatment of COPD. Fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Advair Diskus ® is a type of drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. For people with COPD, Advair Diskus may help prevent and treat symptoms such as: 1,2. Coughing. Chest tightness. Shortness of breath. Wheezing. What are the ingredients in Advair Diskus?
